MedDataX Logo

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

NCT ID: NCT00623623

Last Updated: 2019-08-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1899 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-01

Study Completion Date

2012-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.

The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated.

All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

NCT02777580

Myocardial Infarction
COMPLETED PHASE4

The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study

NCT00882635

Acute Myocardial Infarction
COMPLETED PHASE3

Adjunctive, Low-dose tPA in Primary PCI for STEMI

NCT03335839

Myocardial Infarction Percutaneous Coronary Intervention
COMPLETED PHASE3

Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients

NCT00257309

Acute Myocardial Infarction
TERMINATED PHASE4

Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy

NCT04766437

Non ST Segment Elevation Acute Coronary Syndrome
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tenecteplase

Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention

Group Type EXPERIMENTAL

enoxaparin

Intervention Type DRUG

Adjunctive treatment

catheterisation

Intervention Type PROCEDURE

Routine or rescue coronary intervention

tenecteplase

Intervention Type DRUG

Single, weight-adjusted i.v. bolus of tenecteplase

clopidogrel

Intervention Type DRUG

Adjunctive treatment

primary PCI

Standard primary PCI

Group Type OTHER

primary PCI

Intervention Type PROCEDURE

Standard primary PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

primary PCI

Standard primary PCI

Intervention Type PROCEDURE

enoxaparin

Adjunctive treatment

Intervention Type DRUG

catheterisation

Routine or rescue coronary intervention

Intervention Type PROCEDURE

tenecteplase

Single, weight-adjusted i.v. bolus of tenecteplase

Intervention Type DRUG

clopidogrel

Adjunctive treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age equal or greater than 18 years
2. Onset of symptoms \< 3 hours prior to randomisation 3.12-lead ECG indicative of an acute STEMI

4.Informed consent received

Exclusion Criteria

Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1123.28.43009 Boehringer Ingelheim Investigational Site

Salzburg, , Austria

Site Status

1123.28.43010 Boehringer Ingelheim Investigational Site

Salzburg, , Austria

Site Status

1123.28.43001 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43002 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43003 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43004 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43005 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43007 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.43008 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1123.28.32060 Boehringer Ingelheim Investigational Site

Bornem, , Belgium

Site Status

1123.28.32010 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1123.28.32070 Boehringer Ingelheim Investigational Site

Herentals, , Belgium

Site Status

1123.28.32040 Boehringer Ingelheim Investigational Site

Liège, , Belgium

Site Status

1123.28.55010 Boehringer Ingelheim Investigational Site

Brasília, , Brazil

Site Status

1123.28.55020 Boehringer Ingelheim Investigational Site

Brasília, , Brazil

Site Status

1123.28.55008 Boehringer Ingelheim Investigational Site

Cabo Frio, , Brazil

Site Status

1123.28.55017 Boehringer Ingelheim Investigational Site

Campinas, , Brazil

Site Status

1123.28.55007 Boehringer Ingelheim Investigational Site

Porto Alegre, , Brazil

Site Status

1123.28.55001 Boehringer Ingelheim Investigational Site

Recife, , Brazil

Site Status

1123.28.55018 Boehringer Ingelheim Investigational Site

Rio de Janeiro, , Brazil

Site Status

1123.28.55028 Boehringer Ingelheim Investigational Site

Rio de Janeiro, , Brazil

Site Status

1123.28.55016 Boehringer Ingelheim Investigational Site

Sao Lourenço Do Sul, , Brazil

Site Status

1123.28.55004 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

Site Status

1123.28.55014 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

Site Status

1123.28.11006 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1123.28.11505 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1123.28.11002 Boehringer Ingelheim Investigational Site

Newmarket, Ontario, Canada

Site Status

1123.28.13001 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.13002 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.13003 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.13004 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.13005 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.13006 Boehringer Ingelheim Investigational Site

Santiago, , Chile

Site Status

1123.28.3376A Boehringer Ingelheim Investigational Site

Ambérieu-en-Bugey, , France

Site Status

1123.28.3329A Boehringer Ingelheim Investigational Site

Aubervilliers, , France

Site Status

1123.28.3329B Boehringer Ingelheim Investigational Site

Aubervilliers, , France

Site Status

1123.28.3329C Boehringer Ingelheim Investigational Site

Aubervilliers, , France

Site Status

1123.28.3315A Boehringer Ingelheim Investigational Site

Besançon, , France

Site Status

1123.28.3315B Boehringer Ingelheim Investigational Site

Besançon, , France

Site Status

1123.28.3351A Boehringer Ingelheim Investigational Site

Besançon, , France

Site Status

1123.28.3351B Boehringer Ingelheim Investigational Site

Besançon, , France

Site Status

1123.28.3302A Boehringer Ingelheim Investigational Site

Bobigny, , France

Site Status

1123.28.3302B Boehringer Ingelheim Investigational Site

Bobigny, , France

Site Status

1123.28.3319A Boehringer Ingelheim Investigational Site

Bordeaux, , France

Site Status

1123.28.3319B Boehringer Ingelheim Investigational Site

Bordeaux, , France

Site Status

1123.28.3319C Boehringer Ingelheim Investigational Site

Bordeaux, , France

Site Status

1123.28.3374A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, , France

Site Status

1123.28.3383A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, , France

Site Status

1123.28.3385A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, , France

Site Status

1123.28.3347A Boehringer Ingelheim Investigational Site

Bourges, , France

Site Status

1123.28.3347B Boehringer Ingelheim Investigational Site

Bourges, , France

Site Status

1123.28.3347C Boehringer Ingelheim Investigational Site

Bourges, , France

Site Status

1123.28.3355A Boehringer Ingelheim Investigational Site

Bron, , France

Site Status

1123.28.3355B Boehringer Ingelheim Investigational Site

Bron, , France

Site Status

1123.28.3382A Boehringer Ingelheim Investigational Site

Caluire-et-Cuire, , France

Site Status

1123.28.3311A Boehringer Ingelheim Investigational Site

Châteauroux, , France

Site Status

1123.28.3311B Boehringer Ingelheim Investigational Site

Châteauroux, , France

Site Status

1123.28.3346A Boehringer Ingelheim Investigational Site

Châteauroux, , France

Site Status

1123.28.3346B Boehringer Ingelheim Investigational Site

Châteauroux, , France

Site Status

1123.28.3303A Boehringer Ingelheim Investigational Site

Clichy, , France

Site Status

1123.28.3309A Boehringer Ingelheim Investigational Site

Dreux, , France

Site Status

1123.28.3342A Boehringer Ingelheim Investigational Site

Dreux, , France

Site Status

1123.28.3337A Boehringer Ingelheim Investigational Site

Évecquemont, , France

Site Status

1123.28.3387A Boehringer Ingelheim Investigational Site

Fort de France Cedex, , France

Site Status

1123.28.3388A Boehringer Ingelheim Investigational Site

Fort de France Cedex, , France

Site Status

1123.28.3353A Boehringer Ingelheim Investigational Site

Grenoble, , France

Site Status

1123.28.3353B Boehringer Ingelheim Investigational Site

Grenoble, , France

Site Status

1123.28.3317A Boehringer Ingelheim Investigational Site

La Tronche, , France

Site Status

1123.28.3317B Boehringer Ingelheim Investigational Site

La Tronche, , France

Site Status

1123.28.3307A Boehringer Ingelheim Investigational Site

Le Chesnay, , France

Site Status

1123.28.3339A Boehringer Ingelheim Investigational Site

Le Chesnay, , France

Site Status

1123.28.3339B Boehringer Ingelheim Investigational Site

Le Chesnay, , France

Site Status

1123.28.3336A Boehringer Ingelheim Investigational Site

Le Port-Marly, , France

Site Status

1123.28.3301A Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1123.28.3301B Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1123.28.3325A Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1123.28.3325B Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1123.28.3326A Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1123.28.3318A Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3318B Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3318C Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3356A Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3356B Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3369A Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3369B Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1123.28.3308A Boehringer Ingelheim Investigational Site

Melun, , France

Site Status

1123.28.3308B Boehringer Ingelheim Investigational Site

Melun, , France

Site Status

1123.28.3340A Boehringer Ingelheim Investigational Site

Melun, , France

Site Status

1123.28.3340B Boehringer Ingelheim Investigational Site

Melun, , France

Site Status

1123.28.3379A Boehringer Ingelheim Investigational Site

Montélimar, , France

Site Status

1123.28.3328A Boehringer Ingelheim Investigational Site

Montfermeil, , France

Site Status

1123.28.3328B Boehringer Ingelheim Investigational Site

Montfermeil, , France

Site Status

1123.28.3328C Boehringer Ingelheim Investigational Site

Montfermeil, , France

Site Status

1123.28.3313A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1123.28.3313B Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1123.28.3349A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1123.28.3349B Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1123.28.3322A Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1123.28.3322B Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1123.28.3322C Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1123.28.3366A Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1123.28.3375A Boehringer Ingelheim Investigational Site

Oyonnax, , France

Site Status

1123.28.3331A Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1123.28.3334A Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1123.28.3371A Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1123.28.3357A Boehringer Ingelheim Investigational Site

Pessac, , France

Site Status

1123.28.3338A Boehringer Ingelheim Investigational Site

Poissy, , France

Site Status

1123.28.3316A Boehringer Ingelheim Investigational Site

Pringy, , France

Site Status

1123.28.3352A Boehringer Ingelheim Investigational Site

Pringy, , France

Site Status

1123.28.3341A Boehringer Ingelheim Investigational Site

Quincy-sous-Sénart, , France

Site Status

1123.28.3378A Boehringer Ingelheim Investigational Site

Romans-sur-Isère, , France

Site Status

1123.28.3310A Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3310B Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3344A Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3345A Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3345B Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3345C Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

1123.28.3377A Boehringer Ingelheim Investigational Site

Valence, , France

Site Status

1123.28.3384A Boehringer Ingelheim Investigational Site

Valence, , France

Site Status

1123.28.3373A Boehringer Ingelheim Investigational Site

Vienne, , France

Site Status

1123.28.49002 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1123.28.49006 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1123.28.49008 Boehringer Ingelheim Investigational Site

Dortmund, , Germany

Site Status

1123.28.49012 Boehringer Ingelheim Investigational Site

Duisburg, , Germany

Site Status

1123.28.49052 Boehringer Ingelheim Investigational Site

Frankenthal, , Germany

Site Status

1123.28.49026 Boehringer Ingelheim Investigational Site

Sömmerda, , Germany

Site Status

1123.28.30012 Boehringer Ingelheim Investigational Site

Alexandroupoli, , Greece

Site Status

1123.28.30001 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

1123.28.30003 Boehringer Ingelheim Investigational Site

Chalikida, , Greece

Site Status

1123.28.30006 Boehringer Ingelheim Investigational Site

Corinth, , Greece

Site Status

1123.28.30011 Boehringer Ingelheim Investigational Site

Katerini, , Greece

Site Status

1123.28.30014 Boehringer Ingelheim Investigational Site

Kavala, , Greece

Site Status

1123.28.30002 Boehringer Ingelheim Investigational Site

Livadeia, , Greece

Site Status

1123.28.30005 Boehringer Ingelheim Investigational Site

Thebes, , Greece

Site Status

1123.28.30007 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

1123.28.30010 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

1123.28.30009 Boehringer Ingelheim Investigational Site

Véroia, , Greece

Site Status

1123.28.39201 Boehringer Ingelheim Investigational Site

Ferrara, , Italy

Site Status

1123.28.39002A Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

1123.28.39022 Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

1123.28.39004A Boehringer Ingelheim Investigational Site

Imperia, , Italy

Site Status

1123.28.39200A Boehringer Ingelheim Investigational Site

Lagosanto (FE), , Italy

Site Status

1123.28.39001A Boehringer Ingelheim Investigational Site

Monza, , Italy

Site Status

1123.28.39011 Boehringer Ingelheim Investigational Site

Monza, , Italy

Site Status

1123.28.39082 Boehringer Ingelheim Investigational Site

Pescia (Pistoia), , Italy

Site Status

1123.28.39083 Boehringer Ingelheim Investigational Site

Pescia (Pistoia), , Italy

Site Status

1123.28.39008A Boehringer Ingelheim Investigational Site

Pistoia, , Italy

Site Status

1123.28.39081 Boehringer Ingelheim Investigational Site

Pistoia, , Italy

Site Status

1123.28.39041 Boehringer Ingelheim Investigational Site

Sanremo (IM), , Italy

Site Status

1123.28.47005 Boehringer Ingelheim Investigational Site

Hamar, , Norway

Site Status

1123.28.47001 Boehringer Ingelheim Investigational Site

Oslo, , Norway

Site Status

1123.28.47002 Boehringer Ingelheim Investigational Site

Oslo, , Norway

Site Status

1123.28.19001 Boehringer Ingelheim Investigational Site

Lima, , Peru

Site Status

1123.28.19004 Boehringer Ingelheim Investigational Site

Lima, , Peru

Site Status

1123.28.48002 Boehringer Ingelheim Investigational Site

Gniezno, , Poland

Site Status

1123.28.48006 Boehringer Ingelheim Investigational Site

Gniezno, , Poland

Site Status

1123.28.48009 Boehringer Ingelheim Investigational Site

Grodzisk Wielopolski, , Poland

Site Status

1123.28.48001 Boehringer Ingelheim Investigational Site

Poznan, , Poland

Site Status

1123.28.70005 Boehringer Ingelheim Investigational Site

Chelyabinsk, , Russia

Site Status

1123.28.77005 Boehringer Ingelheim Investigational Site

Chelyabinsk, , Russia

Site Status

1123.28.70009 Boehringer Ingelheim Investigational Site

Irkutsk, , Russia

Site Status

1123.28.77009 Boehringer Ingelheim Investigational Site

Irkutsk, , Russia

Site Status

1123.28.70002 Boehringer Ingelheim Investigational Site

Kemerovo, , Russia

Site Status

1123.28.77002 Boehringer Ingelheim Investigational Site

Kemerovo, , Russia

Site Status

1123.28.70008 Boehringer Ingelheim Investigational Site

Murmansk, , Russia

Site Status

1123.28.77008 Boehringer Ingelheim Investigational Site

Murmansk, , Russia

Site Status

1123.28.77003 Boehringer Ingelheim Investigational Site

Nizhny Novgorod, , Russia

Site Status

1123.28.70003 Boehringer Ingelheim Investigational Site

Nizhnyi Novgorod, , Russia

Site Status

1123.28.70006 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1123.28.70007 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1123.28.77006 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1123.28.70004 Boehringer Ingelheim Investigational Site

Tomsk, , Russia

Site Status

1123.28.77004 Boehringer Ingelheim Investigational Site

Tomsk, , Russia

Site Status

1123.28.70001 Boehringer Ingelheim Investigational Site

Yekaterinburg, , Russia

Site Status

1123.28.77001 Boehringer Ingelheim Investigational Site

Yekaterinburg, , Russia

Site Status

1123.28.38101 Boehringer Ingelheim Investigational Site

Belgrade, , Serbia

Site Status

1123.28.38103 Boehringer Ingelheim Investigational Site

Belgrade, , Serbia

Site Status

1123.28.38104 Boehringer Ingelheim Investigational Site

Belgrade, , Serbia

Site Status

1123.28.38106 Boehringer Ingelheim Investigational Site

Niš, , Serbia

Site Status

1123.28.38107 Boehringer Ingelheim Investigational Site

Niš, , Serbia

Site Status

1123.28.38108 Boehringer Ingelheim Investigational Site

Smederevo, , Serbia

Site Status

1123.28.38109 Boehringer Ingelheim Investigational Site

Šabac, , Serbia

Site Status

1123.28.38110 Boehringer Ingelheim Investigational Site

Vršac, , Serbia

Site Status

1123.28.38111 Boehringer Ingelheim Investigational Site

Zaječar, , Serbia

Site Status

1123.28.38104 Boehringer Ingelheim Investigational Site

Zemun, , Serbia

Site Status

1123.28.38105 Boehringer Ingelheim Investigational Site

Zemun, , Serbia

Site Status

1123.28.34001 Boehringer Ingelheim Investigational Site

Almería, , Spain

Site Status

1123.28.34004 Boehringer Ingelheim Investigational Site

Granada, , Spain

Site Status

1123.28.34003 Boehringer Ingelheim Investigational Site

Huelva, , Spain

Site Status

1123.28.34007 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1123.28.34002 Boehringer Ingelheim Investigational Site

Málaga, , Spain

Site Status

1123.28.34011 Boehringer Ingelheim Investigational Site

Salamanca, , Spain

Site Status

1123.28.44600 Boehringer Ingelheim Investigational Site

Belfast, , United Kingdom

Site Status

1123.28.44610 Boehringer Ingelheim Investigational Site

Belfast, , United Kingdom

Site Status

1123.28.44210 Boehringer Ingelheim Investigational Site

Bristol, , United Kingdom

Site Status

1123.28.44220 Boehringer Ingelheim Investigational Site

Bristol, , United Kingdom

Site Status

1123.28.44200 Boehringer Ingelheim Investigational Site

Chippenham, , United Kingdom

Site Status

1123.28.44620 Boehringer Ingelheim Investigational Site

Dundonald, , United Kingdom

Site Status

1123.28.44110 Boehringer Ingelheim Investigational Site

Leicester, , United Kingdom

Site Status

1123.28.44630 Boehringer Ingelheim Investigational Site

Newry, , United Kingdom

Site Status

1123.28.44100 Boehringer Ingelheim Investigational Site

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Brazil Canada Chile France Germany Greece Italy Norway Peru Poland Russia Serbia Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Temple T, Ly E, Bogaerts K, Sinnaeve P, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators. Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials. Am Heart J. 2025 Jun;284:20-31. doi: 10.1016/j.ahj.2025.02.002. Epub 2025 Feb 12.

Reference Type DERIVED
PMID: 39952376 (View on PubMed)

Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Music LB, Temple T, Ly E, Bogaerts K, Sinnaeve PR, Danays T, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators. Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged >/=75 Years in STREAM-1 and 2. Circ Cardiovasc Interv. 2024 Dec;17(12):e014251. doi: 10.1161/CIRCINTERVENTIONS.124.014251. Epub 2024 Dec 17.

Reference Type DERIVED
PMID: 39689189 (View on PubMed)

Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc. 2016 Jun 13;5(6):e003559. doi: 10.1161/JAHA.116.003559.

Reference Type DERIVED
PMID: 28525886 (View on PubMed)

Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. Heart. 2016 Apr;102(7):527-33. doi: 10.1136/heartjnl-2015-308075. Epub 2016 Jan 18.

Reference Type DERIVED
PMID: 26783237 (View on PubMed)

Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015 Aug 24;4(8):e002049. doi: 10.1161/JAHA.115.002049.

Reference Type DERIVED
PMID: 26304934 (View on PubMed)

Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 2015 May;101(9):692-8. doi: 10.1136/heartjnl-2014-306686. Epub 2015 Feb 17.

Reference Type DERIVED
PMID: 25691510 (View on PubMed)

Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26.

Reference Type DERIVED
PMID: 25161043 (View on PubMed)

Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014 Oct;100(19):1543-9. doi: 10.1136/heartjnl-2014-306023. Epub 2014 Jun 10.

Reference Type DERIVED
PMID: 24916050 (View on PubMed)

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10.

Reference Type DERIVED
PMID: 23473396 (View on PubMed)

Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010 Jul;160(1):30-35.e1. doi: 10.1016/j.ahj.2010.04.007.

Reference Type DERIVED
PMID: 20598969 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-001219-44

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1123.28

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks
NCT00604695 COMPLETED PHASE2
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
NCT03273075 UNKNOWN PHASE4
EROSION II: OCT Guided PPCI in STEMI
NCT03062826 UNKNOWN
EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction
NCT01930682 COMPLETED PHASE4
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
NCT00168792 TERMINATED PHASE4
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
NCT02182011 COMPLETED PHASE3
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
NCT02235389 TERMINATED
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
NCT06736353 COMPLETED
Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
NCT00976092 UNKNOWN PHASE4
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
NCT00275990 COMPLETED PHASE4
Minimal Invasive Procedure for Myocardial Infarction
NCT01360242 COMPLETED PHASE3
Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction
NCT00766740 COMPLETED PHASE4
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256 RECRUITING PHASE4
Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI
NCT02268669 UNKNOWN PHASE4
Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
NCT01336348 COMPLETED PHASE3
Incorporating Supersaturated Oxygen in Shock
NCT04876040 WITHDRAWN NA
Prehospital Evaluation and Economic Analysis of Different Coronary Syndrome Treatment Strategies - PREDICT
NCT00747656 COMPLETED
The RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack
NCT07000266 ACTIVE_NOT_RECRUITING NA
Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI
NCT03435133 COMPLETED NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
NCT04743245 RECRUITING NA
Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)
NCT01791764 COMPLETED
Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
NCT01882179 COMPLETED PHASE3
The Thrombus Aspiration During PCI After Thrombolysis in STEMI
NCT06654453 NOT_YET_RECRUITING NA
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
NCT01327534 COMPLETED PHASE3
Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly
NCT00136929 UNKNOWN NA